Moleculera Biosciences, Inc.
We are a pioneer in the diagnosis, treatment, and monitoring of immune-mediated neuropsychiatric, cardiovascular, Long-COVID, and neurodegenerative disorders.
- Stage Product In Market
- Industry Healthcare Services
- Location Oklahoma City, OK, USA
- Currency USD
- Founded September 2011
- Employees 15
- Incorporation Type C-corp
- Website moleculera.com
Company Summary
Moleculera is a precision medicine company intently focused on the discovery/development of next-generation technologies for the identification, diagnosis, and treatment of patients suffering from immune-mediated neuropsychiatric, cardiovascular, Long-COVID and neuro-degenerative disorders. Our Autoimmune Brain Panel™ has been commercially used by ~16,000 patients in over 50 countries generating ~$13M in cumulative revenue on ~$10M of investment.
Team
-
President & CEOSeasoned biotech professional with over 35 years of industry-leading experience beginning at Genentech. A serial entrepreneur who has co-founded nine companies in molecular testing, diagnostic/medical device and therapeutics. Craig has led five products through FDA 510(k) and taken several companies public. He received his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business.
-
Chief Financial OfficerOver 45 years of strategic financial and operations experience. Began career as CPA at Touche Ross & Co. in 1962. Controller at Elgin National and Columbia Pictures, CFO at Wilkinson Sword. Financial consultant to numerous companies including two biotechnology companies including one publicly traded biotechnology company.
-
Chief Scientific OfficerCo-founder and CSO of Moleculera Biosciences. OUHSC George Lynn Cross Research Professor, over 40 years research in molecular mimicry and immunity, inventor of technology. Over 100+ peer-reviewed publications in high impact journals such as Nature Medicine, Journal of Immunology, Journal of Clinical Microbiology, Neuropsychopharmacology. She has pioneered the development of human mAbs in understanding the pathogenesis of human diseases.
-
VP of Research & Clinical Development (Consultant)30+ years' experience in building successful diagnostic and therapeutic companies from company inception through successful exits, including a $230M exit to Roche. Ph.D. in Biochemistry from Oklahoma State University and postdoctoral training at Dartmouth Medical School.
-
Joe QuashnockLaboratory DirectorExtensive experience as a director in commercial reference laboratories with LabCorp® & newborn screening with PerkinElmer® Genetics. Began career in the US Army as a biochemist in hospital/medical labs. Expertise in quality control, immunoassays, safety, and laboratory regulations. Qualified College of American Pathologists lead inspector. Assisted in writing standards and guidelines for the Clinical and Laboratory Standards Institute.
-
Director of Medical AffairsSpent past 15 years working to improve quality, value, and access in healthcare. 5 years as physician in Clinical Informatics at Epic working with healthcare organizations to optimize use of Epic’s software as a tool to reach system-wide goals. Began career as a General Pediatrician at a large pediatrics practice in Chicago directing the group’s Patient-Centered Medical Home initiatives while also providing inpatient/outpatient pediatrics care.
Advisors
-
James Larimore Crowe & DunlevyUnconfirmed
Previous Investors
-
Innovation to Enterprise (i2E)Unconfirmed
SeedStep Angels and Local InvestorsUnconfirmed
Dr. Brian Clevinger, Prolog VenturesManaging DirectorUnconfirmed -
Dr. Robert CalcaterraUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.